PUBLISHER: Grand View Research | PRODUCT CODE: 2040756
PUBLISHER: Grand View Research | PRODUCT CODE: 2040756
The global clinical trials market size was estimated at USD 89.0 billion in 2025 and is projected to reach USD 158.4 billion by 2033, growing at a CAGR of 7.7% from 2026 to 2033. The market growth is driven by the rising prevalence of chronic and rare diseases, advancements in precision medicine and biotechnology, the expansion of decentralized and virtual trials, and growing R&D investments by pharmaceutical and biotech companies.
The market growth is attributed to the growing trend of outsourcing services, the rising prevalence of chronic conditions such as cancer, diabetes, and neurological disorders, and the increasing demand for innovative therapies.
In addition, a growing number of pharmaceutical and medical device companies, advancements in digital health, personalized medicine, and global partnerships are expected to drive the growth of the clinical trials industry over the forecast period. In addition, supportive government initiatives, advanced regulatory approvals, and increased funding from pharmaceutical and biotech companies further contribute to the global market. Furthermore, global collaborations, increased patient awareness, and improved access to trials are expected to drive recruitment, data quality, and overall success rates across trial populations and regions.
Similarly, significant changes in the conduct of ongoing or upcoming clinical trials are among the factors contributing to market growth. Regulatory agencies, including the U.S. FDA, the European Medicines Agency (EMA), the National Institutes of Health (NIH), and China's National Medical Products Administration, among several others, issued various guidelines for conducting trials to support the implementation of decentralized clinical trials and virtual services. The current scenario for research and development activities across the globe and the need for several new treatment options have also led to the adoption of fast-track clinical trials. Thus, the aforementioned factors are expected to open new opportunities for growth in the clinical trial market.
Furthermore, the utilization of CRO services enables manufacturers and sponsors to focus their resources on strengthening core production capabilities and optimizing in-house operational processes. The availability of a vast array of services, from drug discovery to post-marketing surveillance, has further simplified processes for mid-size & small-scale pharmaceutical and biotechnological organizations by providing them with the option to outsource research and development activities to reduce infrastructure investment. For instance, in May 2025, IQVIA entered into a strategic partnership with the Sarah Cannon Research Institute, known as SCRI Development Innovations. This collaboration is focused on advancing oncology trials for biopharma partners around the globe. By leveraging the strengths of both IQVIA and SCRI Development Innovations, the partnership aims to improve clinical trial processes, overcome operational challenges, enhance data delivery, and expedite patient access to innovative therapies.
Global Clinical Trials Market Report Segmentation
This report forecasts revenue growth at the global, regional & country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global clinical trials market report based on phase, study design, indication, indication by study design, service, sponsor, and region: